Retatrutide operates through a unique mechanism as a triple agonist, targeting the GIP, GLP-1, and GCG receptors, with a strong emphasis on GIP receptor activation [4].
Incretin hormones GLP-1 and GIP stimulate insulin secretion from pancreatic beta cells and contribute to feelings of fullness after eating, while glucagon serves a counter-regulatory function by raising blood glucose levels during fasting.
This receptor interaction leads to a comprehensive approach to metabolic regulation, significantly impacting both glycemic control and weight loss. Below is an overview of the underlying mechanisms:
- Retatrutide’s primary mechanism involves potent activation of the GIP receptor, which plays a vital role in appetite regulation by directly affecting the brain’s satiety centers. This reduces hunger, cravings, and overall food intake [8].
- Through GLP-1 receptor activation, retatrutide supports glycemic regulation and enhances satiety. GLP-1 also slows down gastrointestinal motility and delays gastric emptying, leading to increased feelings of fullness after meals [9,10].
- Activation of the GCG receptor by retatrutide is believed to increase energy expenditure and promote fat oxidation, largely through metabolic actions in the liver. GCG receptor stimulation encourages fat breakdown and elevates metabolic rates. Additionally, it induces “beiging” of white fat, converting it into beige fat with thermogenic properties similar to brown fat, thereby boosting calorie burning and enhancing metabolism [11].
These combined mechanisms make retatrutide a promising option for treating obesity and type 2 diabetes by not only curbing calorie intake but also increasing energy expenditure, offering a dual strategy for effective weight management.
